Creative Biolabs Expands Custom Liposome and LNP Services for Advanced Therapeutic Delivery

Creative Biolabs has significantly expanded its lipid-based drug delivery services, offering advanced custom liposome and lipid nanoparticle (LNP) formulation solutions. These enhanced services are designed to address critical delivery barriers faced by researchers developing next-generation therapeutics, including mRNA, siRNA drugs, protein biologics, vaccines, and gene delivery systems. The platform provides comprehensive support from custom formulation design to particle characterization, stability evaluation, and scalable manufacturing, ensuring payloads are protected, released controllably, and achieve optimal cellular uptake.

The specialized LNP formulation services focus on encapsulating and delivering genetic payloads such as mRNA, siRNA, and gene-editing components. This includes ionizable lipid screening, microfluidic formulation, and extensive particle analysis covering size, PDI, zeta potential, and encapsulation efficiency, crucial for improving intracellular delivery and process scale-up. Complementing this, liposome formulation services cater to proteins, peptides, and small molecules, providing lipid composition optimization, surface modification, and release profile evaluation to meet diverse payload-specific development needs.

Applicable across various therapeutic areas like mRNA vaccines, gene therapy, and oncology, Creative Biolabs' integrated platform extends beyond formulation to offer essential analytical characterization and scale-up guidance, supporting clients from early feasibility through preclinical stages. A senior scientist at Creative Biolabs noted, "Efficient delivery remains a key challenge for next-generation therapeutics. Our lipid-based formulation services help researchers select suitable lipid systems, evaluate critical quality attributes, and optimize delivery performance based on payload type."